Literature DB >> 1893528

Use of antibodies to human O6-alkylguanine-DNA alkyltransferase to study the content of this protein in cells treated with O6-benzylguanine or N-methyl-N'-nitro-N-nitrosoguanidine.

A E Pegg1, L Wiest, C Mummert, L Stine, R C Moschel, M E Dolan.   

Abstract

Antisera raised in rabbits to three peptides corresponding to amino acid sequences found in human O6-alkylguanine-DNA alkyltransferase were used to study the fate of the alkyltransferase protein in human colon tumor cells after exposure to N-methyl-N'-nitro-N-nitrosoguanidine or to O6-benzylguanidine. Under these conditions, the alkyltransferase protein becomes inactivated, presumably by the conversion of its cysteine acceptor site to S-methylcysteine or S-benzylcysteine respectively. It was found that the protein was rapidly degraded after such inactivation both in intact cells and in cell-free extracts. It is probable that a conformational change in the protein is brought about by conversion of the alkyltransferase to the inactive form by alkylation of the cysteine acceptor site. This change may render the protein very sensitive to proteolytic degradation. The rapid degradation of the inactive form of the protein may serve as a signal for its resynthesis but in the short term ensures that its reactivation by regeneration of the cysteine acceptor site is unlikely to occur to any significant extent. The short half-life of the inactivated alkyltransferase protein makes it probable that measurement of the content of the alkyltransferase protein by immunohistochemistry, which is likely to measure the sum of the active and inactivated forms of the protein, will nevertheless yield an accurate estimation of the cellular capacity to repair O6-methylguanine provided that procedures with sufficient specificity and affinity can be developed.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1893528     DOI: 10.1093/carcin/12.9.1679

Source DB:  PubMed          Journal:  Carcinogenesis        ISSN: 0143-3334            Impact factor:   4.944


  19 in total

1.  Degradation of BRCA2 in alkyltransferase-mediated DNA repair and its clinical implications.

Authors:  Subha Philip; Srividya Swaminathan; Sergey G Kuznetsov; Sreenivas Kanugula; Kajal Biswas; Suhwan Chang; Natalia A Loktionova; Diana C Haines; Philipp Kaldis; Anthony E Pegg; Shyam K Sharan
Journal:  Cancer Res       Date:  2008-12-01       Impact factor: 12.701

2.  Active and alkylated human AGT structures: a novel zinc site, inhibitor and extrahelical base binding.

Authors:  D S Daniels; C D Mol; A S Arvai; S Kanugula; A E Pegg; J A Tainer
Journal:  EMBO J       Date:  2000-04-03       Impact factor: 11.598

3.  Point mutations at multiple sites including highly conserved amino acids maintain activity, but render O6-alkylguanine-DNA alkyltransferase insensitive to O6-benzylguanine.

Authors:  M Xu-Welliver; A E Pegg
Journal:  Biochem J       Date:  2000-04-15       Impact factor: 3.857

4.  Recombinant human O6-alkylguanine-DNA alkyltransferase (AGT), Cys145-alkylated AGT and Cys145 --> Met145 mutant AGT: comparison by isoelectric focusing, CD and time-resolved fluorescence spectroscopy.

Authors:  M Federwisch; U Hassiepen; K Bender; M Dewor; M F Rajewsky; A Wollmer
Journal:  Biochem J       Date:  1997-05-15       Impact factor: 3.857

5.  Covalent capture of a human O(6)-alkylguanine alkyltransferase-DNA complex using N(1),O(6)-ethanoxanthosine, a mechanism-based crosslinker.

Authors:  D M Noll; N D Clarke
Journal:  Nucleic Acids Res       Date:  2001-10-01       Impact factor: 16.971

Review 6.  Insight into the cooperative DNA binding of the O⁶-alkylguanine DNA alkyltransferase.

Authors:  Ingrid Tessmer; Michael G Fried
Journal:  DNA Repair (Amst)       Date:  2014-02-16

Review 7.  DNA binding, nucleotide flipping, and the helix-turn-helix motif in base repair by O6-alkylguanine-DNA alkyltransferase and its implications for cancer chemotherapy.

Authors:  Julie L Tubbs; Anthony E Pegg; John A Tainer
Journal:  DNA Repair (Amst)       Date:  2007-05-07

8.  Effect of temozolomide and dacarbazine on O6-alkylguanine-DNA alkyltransferase activity and sensitivity of human tumor cells and xenografts to 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  R B Mitchell; M E Dolan
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

9.  Sequential therapy with dacarbazine and carmustine: a phase I study.

Authors:  R B Mitchell; M E Dolan; L Janisch; N J Vogelzang; M J Ratain; R L Schilsky
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

10.  Temporal cell-type-specific mRNA expression of O6-methylguanine-DNA methyltransferases in liver of rats treated with dimethylnitrosamine.

Authors:  S Takahashi; J Hall; R Montesano
Journal:  Am J Pathol       Date:  1996-02       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.